Xeris Pharmaceuticals
XERS
16.97
+0.35
+2.11%
Xeris Pharmaceuticals
US · XERS
#2862 by market cap
Listed 2018
16.97
+0.35
+2.11%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:57
Recent news
-
Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $21Market Newswire · 2026/11/6
-
Rating change
Xeris Pharmaceuticals (XERS) Receives a Buy From H.C. WainwrightTipRanks · 2025/9/17
-
Rating change
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/9/29
-
Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $18Market Newswire · 2026/11/11
-
Rating change
Piper Sandler Maintains Xeris Pharmaceuticals(XERS.US) With Hold Rating, Maintains Target Price $8Market Newswire · 2026/9/10
-
Rating change
H.C. Wainwright Remains a Buy on Xeris Pharmaceuticals (XERS)TipRanks · 2026/9/22
-
H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $18Market Newswire · 2026/11/6
-
Rating change
Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2025/11/7
-
Rating change
Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $18Market Newswire · 2025/10/29
-
Rating change
Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $9Market Newswire · 2026/5/14
-
Rating change
Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $14Market Newswire · 2026/10/6
-
H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/11/9
-
Rating change
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy RatingMarket Newswire · 2026/7/1
-
Rating change
Leerink Partners Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $16Market Newswire · 2026/9/10
-
Rating change
Piper Sandler Downgrades Xeris Pharmaceuticals(XERS.US) to Hold Rating, Raises Target Price to $8Market Newswire · 2025/11/7
-
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $18Market Newswire · 2026/11/6
-
Rating change
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Xeris Pharmaceuticals (XERS)TipRanks · 2026/3/3
-
Rating change
Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $12Market Newswire · 2026/8/20
-
Rating change
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $12Market Newswire · 2026/7/8
-
Rating change
H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $10Market Newswire · 2026/9/22
-
Rating change
TR | OpenAI - 4o Maintains Xeris Pharmaceuticals(XERS.US) With Hold Rating, Raises Target Price to $7.5Market Newswire · 2025/8/12
-
Rating change
H.C. Wainwright Initiates Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $10Market Newswire · 2025/8/12
-
Rating change
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $11Market Newswire · 2025/8/8
-
Rating change
Leerink Partners Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $9Market Newswire · 2025/8/20
-
Rating change
Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $8Market Newswire · 2025/8/8
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:57:17 · For reference only, not investment advice and not tailored to your situation.
Xeris Pharmaceuticals discussion 0 comments